Nutlin-3

Catalog No.S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

Size Price Stock Quantity  
In DMSO USD 185 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

5 Customer Reviews

  •  

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

    Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

Purity & Quality Control

Choose Selective Mdm2 Inhibitors

Biological Activity

Description Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
Targets
Mdm2 [5]
(Cell-free assay)
180 nM
In vitro

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MlvTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PJNlXDqM7:TR?= Mn\tOFjDqGh? NXS4R4d1[myxY3vzJFI4NU:KQz3pcoR2[2WmIHPlcIwheHKxbHnm[ZJifGmxbjDjc41x[XKjYnzlJJRwKHSqYYSgc4Yh[mG|YXygcIV3\Wy| MXqyOlM2ODV4NR?=
NP69 NX\YXVh6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\WTWM2OD1|MT62PeKyOi53NDFOwG0> MV[yOlI2OjV5NR?=
NP460 NVv3TXF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rINmlEPTB;MkKuPFXDuTFwMUig{txO MXuyOlI2OjV5NR?=
C666-1 NHnpW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHrOYpKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? M1jENFI3OjV{NUe1
C666-1 MkHnR4VtdCCYaXHibYxqfHliQYPzZZk> MXixNEDDvU1? MUK0PEBp MULEUXNQ MoLtd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw MUeyOlI2OjV5NR?=
C666-1  M2O5NmZ2dmO2aX;uJGF{e2G7 M2np[FExKML3TR?= Mki4NlQhcA>? MWLEUXNQ MljFZYN1cX[jdHXzJJRp\SCyNUOgdIF1cHejeTygeZBz\We3bHH0bY5oKHB3MzygdFIyKGGwZDDN[I0z MVyyOlI2OjV5NR?=
C666-1 MkP0RZBweHSxc3nzJGF{e2G7 NFWxZYcyOCEEtV2= M{X3d|Q5Nzd{IHi= NETQXpdFVVOR M132NZNmdnOrdHn6[ZMhSzZ4Nj2xJINmdGy|IITvJINqe3CuYYTpck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NYTqb|lTOjZ{NUK1O|U>
A549 M1XyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nhWlI1KGh? M13DWmlEPTB;MUeuOlghyrFiND61NkDPxE1? MVuyOlEzPTJ|MB?=
A549-NTC NF6zXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW[yOEBp NHK4T4VKSzVyPUG5MlQzKMLzIEGuPVYh|ryP NE\xbo4zPjF{NUKzNC=>
A549-920 MkWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Qc2UzPCCq NGTTVGdKSzVyPUOzMlg2KMLzIESuPFQh|ryP MlS3NlYyOjV{M{C=
CRL-5908 MmLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;MNlQhcA>? MnvPTWM2OD1|OD63NUDDuSB{LkSzJO69VQ>? MmS4NlYyOjV{M{C=
L6 NVnGR2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml22NVDDqM7:TdMg MXmyOE81QC95MjDo Mk[5SG1UVw>? NIWwenVqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? MXeyOVg4OTd7NB?=
C2C12 MnLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXOxNOKh|ryPwrC= NUPuR3VQOjRxNEivO|IhcA>? MW\EUXNQ M2W5eolvcGmkaYTzJINmdGy|IIDyc4xq\mW{YYTpc44h[W6mIHTp[oZmemWwdHnheIlwdg>? NIP1VXAzPTh5MUe5OC=>
MCF-7  M4PlVWZ2dmO2aX;uJGF{e2G7 NVnlUIMzOTEEoN88US=> NIDxXZlFVVOR MULpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> M33VVVI2PzB{N{Cz
DU4475  NE\3ZWtHfW6ldHnvckBCe3OjeR?= MkXqOU8yOC9{MDFOwG0> MWOyOOKhcA>? NIPse5dld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 MnvNNlU2PDdzN{S=
SMMC-7721 NILEPFFHfW6ldHnvckBCe3OjeR?= NVrrWXYyOTBizszN NUDHRVVMPDhiaB?= M2\YZmROW09? M1vkRoNifXOnczDEUmEhTFOEIHThcYFo\Q>? MnfNNlU2PDR|NkG=
SMMC-7721 MkXDSpVv[3Srb36gRZN{[Xl? MY[xNEDPxE1? NUm4cWlyPDhiaB?= M3LmTmROW09? MWXpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg NXv6PZNXOjV3NESzOlE>
SMMC-7721 Mk[zSpVv[3Srb36gRZN{[Xl? NYLKT4ZOOTBizszN NUS1dVM5PDhiaB?= NVXITWNjTE2VTx?= Mny2bY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIHzleoVtKG:owrDJSm5DOcLibWLORS=> M3jtXVI2PTR2M{[x
SMMC-7721 MknYSpVv[3Srb36gRZN{[Xl? NHrvOocyOCEQvF2= NGe5fHE{PiCq MmLHSG1UVw>? MnP3Z4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> MUWyOVU1PDN4MR?=
MCF-7 M2CxSWZ2dmO2aX;uJGF{e2G7 MYWxNOKh|ryP M2LjNlAuOjRiaB?= NUHRUXlVcW6mdXPld{BxPTNiYX7kJJAzOS:FaYCx NH7KeZQzPTR6MkO3Ny=>
OVCAR10 NG\YN2lHfW6ldHnvckBCe3OjeR?= MonONVDDqM7:TR?= NFHmbHQzOWkEoB?= M1WxU2ROW09? MV\pcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz M1\sUVI2PDJ4NUS4
NCI-H23 NECz[GNHfW6ldHnvckBCe3OjeR?= M3XSb|ExyqEQvF2= NE\6WG4zOWkEoB?= M3X1O2ROW09? M3\aZolv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MYSyOVQzPjV2OB?=
A2780 Mn3xSpVv[3Srb36gRZN{[Xl? M2m1XlExyqEQvF2= NVL2OYVLOjGqwrC= M1H5c2ROW09? NH;DfHdqdmO{ZXHz[ZMheDV|IIDyc5RmcW5ibHX2[Yx{ MnHlNlU1OjZ3NEi=
NCI-H23 M3myS2Z2dmO2aX;uJGF{e2G7 NHrC[|cyOMLizszN MkDJNlFpyqB? NVfQSHRXTE2VTx?= M4Cy[YRm[3KnYYPld{B1cGViRn;4UVEhdGW4ZXzz M3rDVlI2PDJ4NUS4
A2780 Ml;USpVv[3Srb36gRZN{[Xl? MYCxNOKh|ryP NVPiT|R1OjGqwrC= M2nyb2ROW09? MWDk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MoXINlU1OjZ3NEi=
HCT116  M3HwZWZ2dmO2aX;uJGF{e2G7 M1[3O|ExKML3TR?= NFnkTJEzPCCq MknQZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 Ml7HNlU{QDByNUW=
MCF-10CA1a MVHGeY5kfGmxbjDBd5NigQ>? MorkNVDDqM7:TR?= M3zBTVQ5KGh? M4rLeGROW09? NXi4fWF{cW6qaXLpeJMh[mG|YXygbY53[XOrb36gZY5lKHKnZIXj[YQhXEeILd8yN{1qdmS3Y3XkJIlvfmG|aX;uJJRwKGKjc3HsJIxmfmWucx?= NGG2VlYzPTJ3N{eyPS=>
MCF-10A1  MXfGeY5kfGmxbjDBd5NigQ>? M1fGeVExyqEQvF2= MVeyOE81QCCq M{fBN2ROW09? M{LR[YlvcGmkaYTzJI1q\3KjdHnvckBw\iCwb4LtZYwh[nKnYYP0JIVxcXSqZXzpZYzDqA>? NGLwRW8zPTJ3N{eyPS=>
MCF-10CA1a NVvVcHFTTnWwY4Tpc44hSXO|YYm= NWXR[FdYOTEEoN88US=> M3u2V|I1KGh? M2PPc2ROW09? NFPvWmtl\WO{ZXHz[ZMhfGinIGTHSk3PujNvaX7keYNm\CCvUl7BJIxmfmWuczDv[m1OWDJuwrDNUXA6NCCjbnVCpIlvfGWpcnnuxsDPusLiMx?= MUmyOVI2Pzd{OR?=
MCF-10CA1a MYHGeY5kfGmxbjDBd5NigQ>? NXTR[3pGOTEEoN88US=> NVX0U|NkOjRiaB?= M3vZOGROW09? MVTpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NFPveoczPTJ3N{eyPS=>
SK-BR-7 NHSzd41HfW6ldHnvckBCe3OjeR?= MlvGNVDDqM7:TR?= MnrWNlQhcA>? MlPXSG1UVw>? MYXpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? Mli0NlUzPTd5Mkm=
SUM102PT M{TyXGZ2dmO2aX;uJGF{e2G7 M13COlExyqEQvF2= MX:yOEBp NIT3XIRFVVOR M4jLeYlvcGmkaYTzJEBVT0ZvzsKzMYlv\HWlZXSgSXBJSjMEoH3SUmEh[W6mIIDyc5RmcW5iZYjwdoV{e2mxbh?= NY\KU|V4OjV{NUe3Nlk>
RAW 264.7 M1PSfGZ2dmO2aX;uJGF{e2G7 NWLrXHQ3OTEEoN88US=> NHnXXI4{OCCvaX6= NXXRRXJDeHKndnXueJMhfGinIIC1N{Bz\WS3Y4Tpc44hcW5icnXzdI9ve2VidH:gUHBU NYPJb2E4OjVzN{K1OFc>
RAW 264.7 Mli3SpVv[3Srb36gRZN{[Xl? MUOxNOKh|ryP NFy3OnE{OCCvaX6= MVvy[YR2[2W|IITo[UBNWFNvYYXncYVvfGWmIITo[UBPTi4QulKgcJVkcW[ncnHz[UBz\XCxcoTldkBo\W6nIHHjeIl3cXS7 MWeyOVE4OjV2Nx?=
RAW 264.7 NF2xT3lHfW6ldHnvckBCe3OjeR?= M4W2b|ExyqEQvF2= NVH3boMxOzBibXnu MmTXbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg NHrKfWczPTF5MkW0Oy=>
MCF7  MlrMR4VtdCCYaXHibYxqfHliQYPzZZk> NU\Pb49JOi53INM1US=> M3fPTVUh\A>? M1LuOGROW09? MWfz[Y5{cXSrenXzJG1ETjdidH:gVGFTWCCrbnjpZol1cW:w Ml\aNlUxQDV7MEK=
MCF7  MXXGeY5kfGmxbjDBd5NigQ>? MoTrNk42KML3TR?= MYO0PEBp M1LpXmROW09? NV\uTYNl\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? Mm\sNlUxQDV7MEK=
ACHN NWTJNFZWS2WubDDWbYFjcWyrdImgRZN{[Xl? NYK2Tm1COC53LUGwJO69VQ>? M4rsfVAuPiCm M4fkfGROW09? Ml3wbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWeyOVA3Pzd6Nx?=
Caki-2 NIfsb|dE\WyuIG\pZYJqdGm2eTDBd5NigQ>? Ml36NE42NTFyIN88US=> M{LiVVAuPiCm Mn\xSG1UVw>? M1PBNolvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M4q0V|I2ODZ5N{i3
A498 MlnwR4VtdCCYaXHibYxqfHliQYPzZZk> M{PvOVAvPS1zMDFOwG0> NFq1PFcxNTZiZB?= NHnGS4ZFVVOR MlL3bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWCyOVA3Pzd6Nx?=
115 MoLCR4VtdCCYaXHibYxqfHliQYPzZZk> NI[4cJIxNjVvMUCg{txO NIHGSHUxNTZiZB?= Mn;ISG1UVw>? NWrlfoV3cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M4i1XFI2ODZ5N{i3
117 NUHEe|RbS2WubDDWbYFjcWyrdImgRZN{[Xl? NWTrTnJvOC53LUGwJO69VQ>? MX:wMVYh\A>? NWW5eoliTE2VTx?= MVTpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MmHRNlUxPjd5OEe=
ACHN Mn\lSpVv[3Srb36gRZN{[Xl? MXWwMlUwOS93IN88US=> MV[0PEBp Mom4SG1UVw>? NEXhNFlt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= MVyyOVA3Pzd6Nx?=
Caki-2 MX\GeY5kfGmxbjDBd5NigQ>? NULiU2RvOC53L{GvOUDPxE1? Mnv2OFghcA>? M2L6NGROW09? MmLocIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NH\YUXIzPTB4N{e4Oy=>
A498 NXfXUlM6TnWwY4Tpc44hSXO|YYm= NX\MSm4xOC53L{GvOUDPxE1? M1L2NFQ5KGh? NEn3ZZlFVVOR M2jvVoxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz NIfuZYgzPTB4N{e4Oy=>
115 M3PF[GZ2dmO2aX;uJGF{e2G7 NIXPRmgxNjVxMT:1JO69VQ>? M1LEUVQ5KGh? MoTCSG1UVw>? MXzs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MXKyOVA3Pzd6Nx?=
ACHN NHL3bGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDOU2x4PSEQvF2= NVXN[4tbPDhiaB?= NVTM[mJITE2VTx?= Mn;6bY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MVGyOVA3Pzd6Nx?=
Caki-2 NITD[XlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7rOUDPxE1? M1;Yc|Q5KGh? MYHEUXNQ MnKxbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg MlfpNlUxPjd5OEe=
A498 M2HP[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7rZXFZPSEQvF2= MlHwOFghcA>? NXPidpp[TE2VTx?= NXXJcHEzcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MYWyOVA3Pzd6Nx?=
115 NIfYbHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULlSYZsPSEQvF2= NEfOeJk1QCCq MnPQSG1UVw>? MlfRbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dNMg NHvDT44zPTB4N{e4Oy=>
ACHN NX3RelNQTnWwY4Tpc44hSXO|YYm= MUK1JO69VQ>? NFPyWIw1QCCq M13QdGROW09? MU\pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi M3TFSlI2ODZ5N{i3
Caki-2 MnnESpVv[3Srb36gRZN{[Xl? M3\NdFUh|ryP MofNOFghcA>? MkLlSG1UVw>? NGDhR5ZqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg Ml\aNlUxPjd5OEe=
A498 MnK0SpVv[3Srb36gRZN{[Xl? MUe1JO69VQ>? NHnzc401QCCq MoXoSG1UVw>? NF;wfYFqdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg MYeyOVA3Pzd6Nx?=
115 Mmr0SpVv[3Srb36gRZN{[Xl? Mo\KOUDPxE1? MoHSOFghcA>? MlSzSG1UVw>? NHnQV41qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M4PkU|I2ODZ5N{i3
MOLM-13 NXzP[ZYyTnWwY4Tpc44hSXO|YYm= M{LQcVbDqM7:TR?= MonONE05KGh? MX;EUXNQ NE\kOHNqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjDwOVMtKE2GTUKsJJAzOSCjbnSgZYNmfHmuYYTl[EBxPTN? MVqyOFg5PTB6Mh?=
MOLM-13 NIG1bIFHfW6ldHnvckBCe3OjeR?= Ml3ZOuKh|ryP NYXM[nNpPiCq NYTXeo5ETE2VTx?= MVPlcohidmOnczD0bIUh[WOndInsZZRqd25ib3[gbIl{fG:wZTDINmIh[W6mIHjlZZQhe2ixY3ugdJJwfGWrboOgTJNxOjdiYX7kJGh{eDly MWWyOFg5PTB6Mh?=
HepG2 NY\mfGN[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfFO|IhcA>? MlOySG1UVw>? NFPjW5JKSzVyPUO1Mlg3KMLzIEKuPUDPxE1? M4C4blI1QDh2OEC5
HepG2/As NUXidmdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrlO|IhcA>? MVjEUXNQ MV;JR|UxRTZ6LkGzJOKyKDlwNjFOwG0> NWHiNJIxOjR6OES4NFk>
SMMC7721 NGWwUodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGCxfVM4OiCq MUXEUXNQ MoH6TWM2OD1|MT6yPEDDuSB2LkKg{txO NEHHO5EzPDh6NEiwPS=>
SMMC7721/Ac M1PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYr2NppYPzJiaB?= NWn6OWd4TE2VTx?= Ml3qTWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? NFrre3QzPDh6NEiwPS=>
Huh-7 NF\BWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1fZA4OiCq NF65foFFVVOR M3HTTWlEPTB;M{OuPVYhyrFiMz65JO69VQ>? M{PZb|I1QDh2OEC5
Hep3B MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvld213PzJiaB?= NY\CWVdTTE2VTx?= NEj2dIZKSzVyPUKwMlE5KMLzIEGuPFQh|ryP M1uyUVI1QDh2OEC5
HepG2 MX;BdI9xfG:|aYOgRZN{[Xl? NYfIVo5zcW6mdXPld{BieG:ydH;zbZM> NVO1[29DOjR6OES4NFk>
SMMC7721 MV\BdI9xfG:|aYOgRZN{[Xl? MWjpcoR2[2W|IHHwc5B1d3Orcx?= NH[1bJIzPDh6NEiwPS=>
Huh-7 NXTjS49oSXCxcITvd4l{KEG|c3H5 MVjpcoR2[2W|IHHwc5B1d3Orcx?= NE[wUHIzPDh6NEiwPS=>
Hep3B M4rTb2Fxd3C2b4Ppd{BCe3OjeR?= M2D1PIlv\HWlZYOgZZBweHSxc3nz MljkNlQ5QDR6MEm=
U2OS  NGHIc5dHfW6ldHnvckBCe3OjeR?= M{e1fVIxKM7:TR?= MnXPNlQhcA>? M{K4[Ylv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NGTiXm8zPDh4N{K1PS=>
AML2 MkS0RZBweHSxc3nzJGF{e2G7 M4rTR|IwOTBizszN NFP2NFUzPC92ODDo Ml;SbY5lfWOnczDhdI9xfG:|aYO= NVjnWZdTOjR4NUm3OFk>
MOML13 MlnoRZBweHSxc3nzJGF{e2G7 NVz4dWhMOi9zMDFOwG0> M3z4SVI1NzR6IHi= NELFWIJqdmS3Y3XzJIFxd3C2b4Ppdy=> M17lWlI1PjV7N{S5
AML2 MW\GeY5kfGmxbjDBd5NigQ>? MUOxNO69VQ>? NFXrbFkzNzRiaB?= MmLybY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= NX3MXHVrOjR4NUm3OFk>
AML3 MojjSpVv[3Srb36gRZN{[Xl? MVWxNO69VQ>? M164bVIwPCCq MoPPbY5kemWjc3XzJJRp\SCuZY\lcEBw\iCyNUO= M4rVOlI1PjV7N{S5
MOML13 MXHGeY5kfGmxbjDBd5NigQ>? M3foOVEx|ryP MnXrNk81KGh? NF76fINqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NEfG[IwzPDZ3OUe0PS=>
BeWo NGXqR4pHfW6ldHnvckBCe3OjeR?= M1zYZlMxKML3TR?= Mk[xNlQhcA>? MWDpcoNz\WG|ZYOgdFU{NCCPZH2yMEBxOjFiYX7kJHB2dWFiYYSgeIhmKHC{b4TlbY4hdGW4ZXy= MYCyOFQ6QDF3NB?=
BeWo M1jlcGFxd3C2b4Ppd{BCe3OjeR?= MmXyN|AhyrWP M2HLRVI1KGh? Mn\FbY5kemWjc3XzJIFxd3C2b4Ppdy=> NXzkNI13OjR2OUixOVQ>
OCI NGHLbZNHfW6ldHnvckBCe3OjeR?= NFX1TZgyOCEQvF2= MV6yOEBp MoHieZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w Mo\iNlQ1PzN3NkK=
MOLM NIS4dVFHfW6ldHnvckBCe3OjeR?= M1:yUVExKM7:TR?= MYOyOEBp NIHhZlB2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= NWnWWIpWOjR2N{O1OlI>
U2OS  NI\abJlHfW6ldHnvckBCe3OjeR?= NX\VRpl7OjBizszN MWGyOEBp NFS1OGJqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw M1\FTFI1OzZ4MEC3
RKO NFfKZYNHfW6ldHnvckBCe3OjeR?= M2rq[FIxKM7:TR?= NFTaPFgzPCCq NET4NIxqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw M4C4dFI1OzZ4MEC3
U2OS  MlfFSpVv[3Srb36gRZN{[Xl? NVLtS2htOjBizszN NVrnOXl2OjRiaB?= MkDXbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= MUGyOFM3PjByNx?=
RKO NGGzN3BHfW6ldHnvckBCe3OjeR?= MUOyNEDPxE1? M4jSOVI1KGh? NH:5[IFqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> M1n6cFI1OzZ4MEC3
SMMC-7721  MWjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXO2XHcxOS5{NT2yNEDPxE1? NY\m[oF1OjRxNEivO|IhcA>? MmLqSG1UVw>? MV3pcohq[mm2czDj[YxtKHC{b3zp[oVz[XSrb36g[I9{\SCjbnSgeIlu\SCmZYDlcoRmdnSueR?= NFPX[5YzPDJ6NkOxNi=>
HuH-7 NYXWUFBNS2WubDDWbYFjcWyrdImgRZN{[Xl? NFTvXJEyNjJ3LUKwJO69VQ>? M3T5eVI1NzR6L{eyJIg> NVf3SnU3TE2VTx?= M2L5XYlvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBld3OnIHHu[EB1cW2nIHTldIVv\GWwdHz5 M4Lp[VI1Ojh4M{Gy
SMMC-7721  MnPFRZBweHSxc3nzJGF{e2G7 NELBSnIzOCEQvF2= MYe0PEBp NH70VZFFVVOR NEHkToRqdmS3Y3XzJIFxd3C2b4Ppdy=> NYH2UZdMOjR{OE[zNVI>
HuH-7 MX3BdI9xfG:|aYOgRZN{[Xl? NH2wTmQzOCEQvF2= MnTEOFghcA>? NEnlb5BFVVOR M4OydIlv\HWlZYOgZZBweHSxc3nz MoS4NlQzQDZ|MUK=
SMMC-7721  NVPYXIl6TnWwY4Tpc44hSXO|YYm= MnfxNVAh|ryP M4Xv[|M3KGh? NWG1UVYyTE2VTx?= M1;IVIRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ MVeyOFI5PjNzMh?=
HuH-7 NEfRPY1HfW6ldHnvckBCe3OjeR?= NGHqd5YyOCEQvF2= Mlz3N|YhcA>? NFz6RXhFVVOR M2LKNIRwf25vcnXneYxifGW|IITo[UBxem:2ZXnuJIV5eHKnc4Ppc44hdGW4ZXygc4YheGixc4Doc{1U\XJ|OUKtdFU{ NVjycmJ7OjR{OE[zNVI>
AT2 NE\vdlFHfW6ldHnvckBCe3OjeR?= MYi1M|ExKM7:TR?= NXfNTFBCdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MmfjNlQzPDB{MEO=
REH MnfLSpVv[3Srb36gRZN{[Xl? NXHRdHlwPS9zMDFOwG0> NEj0e2ht\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= M1HubFI1OjRyMkCz
UoCB6 NGTOeVBHfW6ldHnvckBCe3OjeR?= MY[1M|ExKM7:TR?= NXXFS2NGdGWjZIOgeI8h[SC|dXLzeIFvfGmjbDDhZ4N2dXWuYYTpc44hd2ZidHjlJJA2OyCycn;0[YlvKGG|IIflcIwh[XNidHjlJIV5eHKnc4Ppc44hd2ZiaYTzJIRqemWldDD0ZZJo\XS|IICyNUwhVUSPMjDhcoQhfGinIIDyc{1ieG:ydH;0bYMhSkG[IHHu[EBRXU2DIIDyc5RmcW6|wrC= MYOyOFI1ODJyMx?=
AT2 NFztSoNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MX:wMVI2KM7:TR?= NGm5Z4VqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 Mn7VNlQzPDB{MEO=
REH M33hSGNmdGxiVnnhZoltcXS7IFHzd4F6 MXKwMVI2KM7:TR?= NVHJXnlScW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M1fPdVI1OjRyMkCz
UoCB6 NHO2dnhE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF\kZmwxNTJ3IN88US=> MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 M4PsS|I1OjRyMkCz
A2780 NWDGeIRiTnWwY4Tpc44hSXO|YYm= M3X6cVUwOTBxMkCg{txO Ml\yNlQhcA>? MYL1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? MVSyOFE{PjF2Nx?=
H460 Ml3vSpVv[3Srb36gRZN{[Xl? NXHTenR2PS9zMD:yNEDPxE1? NXjrN4dCOjRiaB?= M3XZepVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi M2WxPVI1OTN4MUS3
Lovo  NF3hUXpHfW6ldHnvckBCe3OjeR?= NH3BfJE2NzFyL{KwJO69VQ>? M2nVXFI1KGh? NVy1PZFqfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= M{D5RVI1OTN4MUS3
A2780 Ml\hRZBweHSxc3nzJGF{e2G7 MlvqOU8yOC9{MDFOwG0> MX2yOEBp MXTlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MmfhNlQyOzZzNEe=
H460 MVPBdI9xfG:|aYOgRZN{[Xl? MVO1M|ExNzJyIN88US=> MkW2NlQhcA>? M4nreIVvcGGwY3XzJIFxd3C2b4Ppd{BqdmS3Y4Tpc44h[nliREK2PWgwTTF7NWKgc5ZmeiC{aGTSRWlN MU[yOFE{PjF2Nx?=
Lovo  MlXTRZBweHSxc3nzJGF{e2G7 NVLVdFV1PS9zMD:yNEDPxE1? MVuyOEBp NYW1RpR6\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NXX3OGFFOjRzM{[xOFc>

... Click to View More Cell Line Experimental Data

In vivo Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

Protocol

Kinase Assay:

[1]

+ Expand

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
Cell Research:

[1]

+ Expand
  • Cell lines: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • Concentrations: Dissolved in DMSO, final concentrations ~ 30 μM
  • Incubation Time: 8, 24, and 48 hours
  • Method:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • Formulation: Formulated in 2% Klucel, 0.5% Tween 80
  • Dosages: 200 mg/kg
  • Administration: Orally, twice a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 581.5
Formula

C30H30Cl2N4O4

CAS No. 890090-75-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • Answer:

    It is a racemate.

Mdm2 Signaling Pathway Map

Related Mdm2 Products0

Tags: buy Nutlin-3 | Nutlin-3 supplier | purchase Nutlin-3 | Nutlin-3 cost | Nutlin-3 manufacturer | order Nutlin-3 | Nutlin-3 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID